1-5 of 5
James Cassidy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial

Josep Tabernero, Rocio Garcia-Carbonero, James Cassidy, Alberto Sobrero, Eric Van Cutsem, Claus-Henning Köhne, Sabine Tejpar, Oleg Gladkov, Irina Davidenko, Ramon Salazar, Liubov Vladimirova, Sergey Cheporov, Olga Burdaeva, Fernando Rivera, Leslie Samuel, Irina Bulavina, Vanessa Potter, Yu-Lin Chang, Nathalie A. Lokker, Peter J. O'Dwyer
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (9): 2541–2550.
https://doi.org/10.1158/1078-0432.CCR-13-0107
Published: 30 April 2013
View article titled, Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial
Open the PDF for Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial in another window
Includes: Supplementary data
Journal Articles

A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules

Alan V. Boddy, E. Ruth Plummer, Radha Todd, Julieann Sludden, Melanie Griffin, Lesley Robson, James Cassidy, Donald Bissett, Alberto Bernareggi, Mark W. Verrill, A. Hilary Calvert
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7834–7840.
https://doi.org/10.1158/1078-0432.CCR-05-0803
Published: 08 November 2005
View article titled, A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules
Open the PDF for A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules in another window
Journal Articles

Phase I Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor in Patients with Refractory Solid Tumors

Gernot Beutel, Hilary Glen, Patrick Schöffski, Jon Chick, Stan Gill, James Cassidy, Chris Twelves
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (15): 5487–5495.
https://doi.org/10.1158/1078-0432.CCR-05-0104
Published: 01 August 2005
View article titled, Phase I Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor in Patients with Refractory Solid Tumors
Open the PDF for Phase I Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor in Patients with Refractory Solid Tumors in another window
Journal Articles

Pharmacokinetic and Pharmacodynamic Evaluation of the Glycinamide Ribonucleotide Formyltransferase Inhibitor AG2034

Howard L. McLeod, James Cassidy, Robert H. Powrie, David G. Priest, Mark A. Zorbas, Timothy W. Synold, Stephen Shibata, Darcy Spicer, Donald Bissett, Yazdi K. Pithavala, Mary A. Collier, Linda J. Paradiso, John D. Roberts
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (7): 2677–2684.
Published: 01 July 2000
View article titled, Pharmacokinetic and Pharmacodynamic Evaluation of the Glycinamide Ribonucleotide Formyltransferase Inhibitor AG2034
Open the PDF for Pharmacokinetic and Pharmacodynamic Evaluation of the Glycinamide Ribonucleotide Formyltransferase Inhibitor AG2034 in another window
Journal Articles

Regulation of Dihydropyrimidine Dehydrogenase in Colorectal Cancer

Stephen J. Johnston, Susan A. Ridge, James Cassidy, Howard L. McLeod
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (9): 2566–2570.
Published: 01 September 1999
View article titled, Regulation of Dihydropyrimidine Dehydrogenase in Colorectal Cancer
Open the PDF for Regulation of Dihydropyrimidine Dehydrogenase in Colorectal Cancer in another window